2012 Annual Report

Alzheimer’sDrug DiscoveryFoundation

ConqueringAlzheimer’sThroughDrugDiscoveryAnnual Report 2012

For more information about the ADDF, please visitwww.AlzDiscovery.org

Millions of people worldwide suffer from Alzheimer’s and related dementias,

without hope of survival. But there is hope in drug discovery.

The ADDF is committed to pursuing the most promising research to find

effective treatments that can be brought quickly to patients.

100% of your donation goes directly to Alzheimer’s drug research and

related programs. With your help, we can and will understand, treat,

prevent and conquer this disease.

With my deepest thanks,

Leonard A. LauderCo-Chairman

Drug discoverymatters.

2

Mission

The mission of the Alzheimer’s Drug Discovery Foundation (ADDF)

is to rapidly accelerate the discovery of drugs to prevent, treat and

cure Alzheimer’s disease, related dementias and cognitive aging.

Approach

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder

of the Estée Lauder cosmetics family, the ADDF provides funding

to leading scientists who are conducting the most promising,

innovative Alzheimer’s drug research worldwide.

Our goal is to provide seed funding for early-stage drug research

that may otherwise go unfunded. By supporting cutting edge,

diverse, novel research projects around the globe, we increase the

chance of finding a cure.

100% of your donation goes directly to Alzheimer’s drug

research and related programs. All of the ADDF’s administrative

and overhead costs are covered by a private foundation.

Many of the ADDF’s grants are structured as investments,

providing a return that is reinvested in new drug research.

Impact

The ADDF has invested nearly $60 million to fund over 400

Alzheimer’s drug discovery programs and clinical trials in

academic centers and biotechnology companies in 18 countries.

3For more information about the ADDF, please visitwww.AlzDiscovery.org

Thanks to your support and generosity, 2012 was a year of significant growth for the Alzheimer’s DrugDiscovery Foundation:

� We raised $9.2 million for research towards finding a cure, funding 37 scientific grants worldwide.One hundred percent of your contributions went directly to fund Alzheimer’s drug discovery andrelated programs.

� The U.S. Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test forAlzheimer’s and other causes of cognitive decline. ADDF provided the critical seed funding neededto launch the test’s early development.

� The ADDF/Belfer ApoE Therapeutics Innovation Program funded 3 projects to develop new drugstargeting Apolipoprotein E — a significant genetic risk factor for Alzheimer’s.

� We funded 6 human clinical studies via our Program to Accelerate Clinical Trials (PACT), withspecial thanks to major support from Nancy and Mel Goodes, The Charles Evans Foundation andThe W. Garfield Weston Foundation.

� The National Institutes of Health (NIH) announced a $7.9 million grant to Suzanne Craft, PhD,at the University of Washington for a five-year clinical trial to evaluate an insulin nasal spray inAlzheimer’s patients. ADDF provided the critical early support for Dr. Craft’s program leading to thisextended study.

� We registered our first international affiliate, ADDF-Canada, to expand funding for promising clinicaltrials in Canada.

� We hosted 2 international scientific conferences and held several signature events across thecountry. Gala highlights included honoring Nancy Reagan and fashion designer Carolina Herrera atour Great Ladies Luncheon and Fashion Show in Washington, DC and hosting an inaugural Hope on theHorizon Chicago Dinner with a special performance by legendary singer and guitarist Glen Campbelland his family.

There has never been a greater need for the ADDF. We received over 400 requests for funding new drugsfrom academic scientists and biotechnology companies across the world in 2012, up almost 40% from 2011.

Thank you for your continued commitment — with your help, we can move quickly towards conqueringthis disease.

Howard Fillit, MD Nancy LynnExecutive Director and Executive Director andChief Science Officer Chief Operating Officer

A Letter fromDr. Howard Fillit andNancy Lynn

Promise ThroughDrugs

The ADDF is committed to investing in a diverse portfolio of research programsand strengthening our network of partnerships until we discover a cure.

The ADDF focuses its funding entirely on preclinical drug discovery researchand early-stage clinical trials involving new drug targets that hold greatpromise but may not be far enough along in the drug development pipeline toreceive financial support from the pharmaceutical industry, investors or otherpartners. The ADDF bridges this critical gap in funding between basic researchand later stage drug development, enabling the scientific pursuit of manyinnovative and novel therapies that might otherwise go unexplored.

Our Funding Model — Venture Philanthropy

The ADDF is a biomedical venture philanthropy. Most of our grants arestructured as mission-related investments, providing a return that isreinvested in new drug research. From more than $14 million investedin biotechnology programs, $2.8 million has been returned to date andimmediately reinvested in new drug research programs. Subsequent tothe ADDF’s initial funding, our grantees have received commitments of over$2 billion in follow-on funding from government, pharmaceutical companiesand venture capital firms to further advance their drug research.

100% of your donation goes directly to Alzheimer’s drug researchand related programs.

ADDF's focus on drug discovery is unique.

Basic Research

Diagnosis and Disease Monitoring

Translational Research and Clinical Interventions

Alzheimer’s Association

Alzheimer’s Drug Discovery Foundation (ADDF)

Alzheimer’s Research UK

Department of Veterans Affairs

National Institutes of Health

0% 25% 50% 75% 100%

Reference: http://iadrp.nia.nih.gov/cadro-web/

International Survey of Funding for Alzheimer’s Disease

4

WhereWe Fund

Canada China

Belgium

United Kingdom

Ireland

Netherlands

Sweden

Germany

Austria

SwitzerlandUnited States Taiwan

Spain

France

Italy

Israel

Australia

The ADDF supports the most promising and diverse research projects around the world.

Finland


ADDFDrugs in the Pipeline

Therapeutic TargetPreclinical ClinicalScreening/ Animal IND-Chemistry Studies Enabling Phase I Phase II Phase III

FDAApproval

Prana Biotechnology* PBT2

Amyloid*

Cognition Therapeutics* PI Aβ blockers

Simon Fraser University* Alectos, MERCK O-glcNAcase modulators

Tau*

New York University* NIH Tau immunotherapy

Yuma Therapeutics* NIH HSP90 Inhibitors

Duke University* Proteosome Activators

Rockefeller University* Riluzole

Neuroprotection*

Emory University* Atomoxetine (Strattera®)

University of California, San Diego* Ceregene NGF gene therapy

PharmatrophiX* NIH NGF mimetics

Northwestern University* Neuroinflammation blockers

Boston University* Klotho activators

AgeneBio* PI GABA a5 ligands

University of Toronto* Angiotensin Receptor Blockers

ApoE & Vascular*

ReXceptor* Bexarotene (co-funded by Bright Focus andCase Western)

Duke University* Cognosci ApoE3 mimetic

Weill Cornell* ApoE gene therapy

Madera* ApoE inducers

Seattle Institute* NIH Intranasal Insulin

Energy Utilization*

Imperial College London*

Metabolic Solutions* Mitoglitazone

Mayo Clinic* Mitochondria protectors

University of Pennsylvania* Avid, LILLY Florbetapir (Amyvid™)

Early Detection & Diagnosis*

Ohio State University* Tau imaging agents

Tel Aviv University* Neurophage NPT001

Zapaq, Inc./Comentis* Astellas β-secretase Inhibitor

University of California, Irvine* NIH Allopregnanalone

The ADDF has granted nearly $60 million to fund over 400 Alzheimer’s drug discoveryprograms and clinical trials in academic centers and at biotechnology companies in18 countries. Below, we highlight select programs, grouped by therapeutic category.

Pre-ADDFFunding

ADDFCatalytic/GapFunding

Follow-on Funding(funder/partner(s)noted)

* Biotechnology Companies* NIH=National Institutes of Health PI=Private Investor

6

Liraglutide (co-funded by Alzheimer’s Society,UK;in-kind support from NovoNordisk and GE)

Spotlight onAmyvid

In 2012, the U.S. Food and Drug Administration (FDA) approved Amyvid™, the first diagnostictest for Alzheimer’s disease. The ADDF provided crucial seed funding for the research ofAmyvid from 2000-2004. This successful technology is an important proof-of-concept for theADDF model, showcasing how early financial support for high-risk projects can lead to andaccelerate the development of innovative drugs and diagnostics in Alzheimer’s.

Brain scan images will appear blurry.

“ADDF's research support and commitment hasbeen critical to the development of amyloid imagingtechnology. These are important assets in both researchand clinical settings to identify beta-amyloid plaques,a neuropathological feature of Alzheimer’s disease.

Thanks to amyloid imaging agents like Amyvid and otherrelated biomarkers, the field can now attempt preventiontrials of Alzheimer’s— trials conducted under largepublic-private partnerships—designed to test whetherearly detection and early intervention can actuallyprevent the onset of symptoms.We hope this area ofresearch, enabled by early investment from theADDF,provides answers for patients and their loved ones.”

— Daniel Skovronsky, MD, PhDFounder and CEO, Avid Radiopharmaceuticals

Left: Amyvid PositiveScan. Moderate tofrequent amyloid plaquesare present, indicating apossible diagnosis ofAlzheimer's or othercognitive diseases.

Right: Amyvid NegativeScan. Sparse to noamyloid plaques arepresent, indicating anunlikely diagnosis ofAlzheimer's or othercognitive diseases.


Select Current Programs and Partnerships

Preclinical DrugDiscovery

The ADDF’s preclinical programfunds research focused ontranslating the knowledge wehave gained about theunderlying causes of Alzheimer’sdisease into drugs. In 2012, 60%of our funding went towardspreclinical drug discovery.

Carmela R. Abraham, PhDBoston UniversitySchool of MedicineBoston, Massachusetts

Dr. Abraham and her team aredeveloping compounds toincrease Klotho expression, a“longevity” target, to preventage-related cognitive declineand Alzheimer’s disease.Interestingly, the gene Klotho isnamed after the Greek goddesswho spins the thread of life.

Biotechnology

The ADDF helps create newbiotechnology companies andfunds early stage biotechnologycompanies, with programsdedicated to Alzheimer’sdisease drug discovery. To date,the ADDF has funded almost 60biotechnology programs.

Lawrence Wennogle, PhDIntra-Cellular Therapies, Inc.New York, New York

Dr. Wennogle’s research aims tofurther test several drugs thatinhibit the casein kinase I (CKI)protein, a protein involved inregulating sleep cycles and thatcould impact multiple aspects ofthe Alzheimer’s disease process.

Program to AccelerateClinical Trials (PACT)

The ADDF’s PACT supportsthe testing of promisingdrugs for Alzheimer’s inhumans, giving innovativeprograms the chance togenerate important safetyand “proof-of-concept” data.The ADDF has funded 29clinical trials.

Olga Meulenbroek, PhDRadboud UniversityMedical CentreNijmegen, The Netherlands

Dr. Meulenbroek and her teamare testing whether nilvadipine,a calcium channel blocker FDAapproved for treating high bloodpressure, can increase bloodflow to the brain, improve bloodpressure stability, and ultimatelyimprove cognition inAlzheimer’s patients.

ADDF Partnership Grant Programs

8

The ADDF/Belfer ApoETherapeutics InnovationProgram

The ADDF and the Robert A. andRenée E. Belfer Family Foundationestablished the ADDF/Belfer ApoETherapeutics Innovation Programto accelerate the development ofnovel therapeutics specificallydesigned to target apolipoproteinE (ApoE), the most significantgenetic risk factor for late-onsetAlzheimer’s. Eight projects havebeen funded through the program.

Mary Jo LaDu, PhDUniversity of Illinois at ChicagoChicago, Illinois

Dr. LaDu’s research aims tounderstand exactly how bexarotene,a cancer drug entering humantesting, boosts ApoE levels andclears amyloid-beta protein. Resultsfrom this study will allow scientiststo create more effective and safeApoE-targeted drugs.

ADDF-Canada

In 2012, the ADDF launchedits first international affiliate,ADDF-Canada. ADDF-Canadawill provide funding toCanadian academicinstitutions and medicalcenters engaged in drugdiscovery and clinical trialsto advance the developmentof novel therapeuticsand diagnostic tools forAlzheimer’s disease, relateddementias and cognitive aging.

—

Sandra Black, MD, FRCP(C)Sunnybrook Research InstituteUniversity of TorontoToronto, Canada

Dr. Black and her team are conductinga clinical trial to determine whethermedication already being used totreat hypertension has the abilityto protect against brain degenerationin people with or at risk fordeveloping Alzheimer’s.

“In today's challengingfunding environment forscientific research, theawards I received fromtheADDFwere justwhat I needed as I wasbeginning to transitionfrom basic research todrug development.”

— Carmela R. Abraham, PhD

Aging and Alzheimer’sPrevention Program

The mission of ADDF’s Aging andAlzheimer’s Prevention Program isto provide a credible independentscientific voice — for the publicand the scientific community —that evaluates the evidence forpharmaceuticals, supplements andnatural products that are claimed toprevent or delay cognitive agingand Alzheimer’s (e.g., fish oil,coffee, and many others).


10

Special Events To broaden awareness and raise critical funds for Alzheimer’s drug research, the ADDF

Sixth Annual Connoisseur’sDinner: To Live is to Think

Sotheby’s | New York, NYApril 26, 2012

Executive ChairsLeonard A. LauderNancy Corzine

The ADDF’s sixth annualConnoisseur’s Dinner raised $1.5million for scientific drug researchfor Alzheimer’s. Nancy and MelGoodes were awarded the secondannual Chairman’s Award, andSotheby’s Chairman, Jamie Niven,conducted the annual “Fund aScientist” live auction, raising arecord $447,900 onsite.

Clockwise from top left: Nancyand Mel Goodes. Nancy Corzine.Liz and Randal Sandler.

Top and right: Dr. Howard Fillit, Nancy Lynn, Leonard A. Lauder,Andrea Mitchell. Norah O'Donnell, Carolina Herrera.

Second Annual Great LadiesLuncheon and Fashion Show

The Ritz-Carlton | Washington, DCMay 2, 2012

Executive ChairsRonald FraschLeonard A. LauderElise and Marc Lefkowitz

In partnership with Saks Fifth Avenue,the ADDF’s second annual Great LadiesLuncheon and Fashion Show raised$270,000. Highlights includedhonoring former First Lady NancyReagan and a fashion presentation bydesigner Carolina Herrera.


hosted five major special events.

Aspen Dinner

Maroon Creek Club | Aspen, COAugust 1, 2012

Executive ChairsLeonard LauderAlison and Buzz Zaino

The ADDF’s signature event in Aspenfeatured a keynote presentation byDr. Fillit, remarks by filmmaker JamesKeach and actress Jane Seymour, anda special preview of Glen Campbell's“Goodbye Tour” documentary.Campbell was diagnosed withAlzheimer's in 2011.

Clockwise from top left: Laura Lauder, Leonard A. Lauder. Buzz and Alison Zaino.Dinner at the Maroon Creek Club.

Left and above: Carolina Herrera model.Marc and Elise Lefkowitz.

“Mymother generously and selflessly gaveher time and energy to the causes shebelieved in.WhenAlzheimer’s diseasetook her life, we searched for a long time

to find the right organizationto support in hermemory.We found theADDF anddecided to do all that we canto ensure that future familiesdo not have to endure theheartbreak of losing a lovedone to this terrible disease.”

— Elise Gelman Lefkowitz

12

Inaugural Hope on the HorizonChicago Dinner

The Art Institute of Chicago | Chicago, ILNovember 5, 2012

Executive ChairsLeonard A. LauderNancy and A. Steven Crown

The ADDF’s inaugural Hope on the HorizonChicago Dinner, hosted by award-winningactress Jane Seymour, brought together265 guests and raised nearly $1.5 millionfor Alzheimer’s drug discovery research.Legendary guitarist and singer GlenCampbell performed selections from his“Goodbye Tour.”

Clockwise from top left: Alice Shure, Christopher Johnson, Bonnie Pfeifer Evans.Dr. Steven J. Romano, Paula Zahn. The Honorable Christine Quinn, William Lauder.Robert and Renée Belfer.

Top and left: Glen Campbell,Ashley Campbell. Eric Lefkofsky,Nancy Crown, Lester Crown.

3rd Annual Hope on the HorizonFall Luncheon & Symposium

Metropolitan Club | New York, NYSeptember 27, 2012

Executive ChairsLeonard A. LauderSir Evelyn and Lady Lynn Forester de RothschildNancy and Mel Goodes

The ADDF’s third annual Fall Luncheon &Symposium brought together more than265 guests and raised nearly $700,000 forAlzheimer’s drug discovery research. The secondannual Charles Evans Award was presented toChristopher Johnson, son of former New YorkGiants running back Ron Johnson who wasdiagnosed with Alzheimer’s in 2008.


ADDF's Science Team with young scholarship winners.

The ADDF’s scientific conferences promote the exchange of ideas, the sharing of research results,and the formation of strategic alliances to further drug development goals.

The ADDF also hosted or exhibited at several other conferences in collaboration with other scientific institutions.

Conferences, Training and Resources

ADDF ACCESS Program

Drug discovery is a team effort, requiring collaboration between scientists with many differenttypes of experience, from biology to chemistry to pharmacology. To help scientists find accessto the expertise they need, the ADDF established the ADDF ACCESS program in 2012. Theprogram connects scientists with networks of collaborators, consultants, contract research

organizations (CROs) and experimental tools. It provides Alzheimer’s scientists with educational materials on the drugdiscovery process and guidance and expertise on the process of selecting and managing CRO relationships. For moreinformation about the ADDF ACCESS Program, visit http://www.alzdiscovery.org/research-and-grants/addf-access/.

6th Drug Discovery for NeurodegenerationConference: An Intensive Course on TranslatingResearch into Drugs

New York, NY | February 12-14, 2012

The ADDF’s annual conference, planned in conjunctionwith the National Institutes of Health, attractedapproximately 140 academic, industry and governmentscientists from around the world. Designed to advancethe development of new drugs for neurodegenerativediseases, the conference educated scientists on theprinciples and practice of drug discovery.

13th International Conference on Alzheimer’sDrug Discovery

Jersey City, NJ | September 10-11, 2012

This global conference, designed to accelerate thedevelopment of innovative treatments, attractedapproximately 140 key stakeholders from thepharmaceutical, biotechnology, government andacademic communities. The ADDF’s funded investigatorsand top-level scientists in the field presented theircurrent research and provided progress.

Support Alzheimer’s Research

Alzheimer’s is a progressive, fatal neurodegenerative disease and the most common

cause of dementia. There are currently no drugs available that prevent or even slow its

course, but scientists are making measurable progress towards finding treatments.

In 2012, an estimated 5.4 million Americans suffered from Alzheimer’s; by 2050, that

number is expected to triple. With an aging population and increasing number of people

with Alzheimer’s, it is critical we continue to invest in research and discover a cure.

There is hope in drug discovery. With your support, we can and will understand,

prevent and conquer this disease.

Please give generously today at www.AlzDiscovery.org

100% of your donation goes directly to Alzheimer’s drug research and related programs.

14

Over $1,000,000AnonymousThe Robert A. and Renée E. Belfer

Family FoundationThe Charles Evans Foundation

Mrs. Bonnie Pfeifer Evans, Co-TrusteeMrs. Alice Shure, Co-Trustee

Mr. and Mrs. Melvin R. GoodesEvelyn H. Lauder Charitable TrustThe W. Garfield Weston Foundation

$100,000 to $999,999The Association for Frontotemporal

DegenerationBrightFocus FoundationThe Charles River LaboratoriesMs. Nancy CorzineThe Estée Lauder Companies Inc.Mr. and Mrs. Nathan KirshMr. Leonard A. LauderThe Leonard and Evelyn Lauder FoundationMr. and Mrs. Marc LefkowitzLewy Body Dementia AssociationNational Institutes of HealthMr. and Mrs. Randal B. Sandler

$50,000 to $99,999AnonymousAetna FoundationMr. and Mrs. David M. BaldwinThe Bluhm Family Charitable FoundationMr. and Mrs. A. Steven CrownMr. and Mrs. James S. CrownMr. and Mrs. Raymond DalioSir Evelyn and Lady Lynn Forester de

RothschildLeslie and Roslyn Goldstein FoundationMr. and Mrs. Richard GoodmanMr. and Mrs. Jim Gordon,

The Edgewater FundsGraff DiamondsMr. and Mrs. Kenneth C. GriffinMs. Dina Merrill Hartley and

Mr. Ted HartleyMrs. Bonnie Englebardt Lautenberg and

Senator Frank LautenbergThe Lefkofsky Family FoundationChristy and John Mack FoundationMr. and Mrs. Barry L. MacLeanNew York Academy of SciencesMr. and Mrs. J.B. Pritzker

Mr. and Mrs. J. Christopher ReyesMr. and Mrs. Andrew RosenfieldMr. and Mrs. JohnW. RoweMr. and Mrs. Michael J. SacksMr. and Mrs. Gordon SegalMr. and Mrs. Peter J. SolomonThe Spiritus Gladius FoundationTishman Speyer Properties, LPMr. and Mrs. Byron D. Trott

$25,000 to $49,999Alzheimer's Foundation of AmericaMr. and Mrs. Jeffrey S. AroninBloomberg LPMs. Carol Seabrook BoulangerMr. and Mrs. John A. CanningMr. and Mrs. James CohenMs. Francie ComerCondé NastMr. and Mrs. Howard DraftMr. and Mrs. Mitchell EichenErnst & Young, LLPFirst Republic BankThe Samuel Freeman Charitable TrustTeauman and Grace Fuite FoundationMr. Philip H. Geier, Jr.Mrs. Judy GlickmanThe Lauder FoundationLe Papillon Ltd. / Mr. Watson J. Warriner, Jr.Mr. and Mrs. Laurence C. Leeds, Jr.Lilly USA, LLCMr. Philip LovettMerck Research LaboratoriesThe David A. and Mildred H. Morse

Charitable TrustNorthern TrustMr. and Mrs. Thomas S. RickettsMs. Lois RobbinsMr. and Mrs. William C. RudinSotheby'sMs. Joan Sutton StrausMr. and Mrs. Michael WeismanWorld Events Forum, Inc.Mr. and Mrs. Buzz Zaino

$10,000 to $24,999Abbott LaboratoriesMr. and Mrs. Robert BaizerBaxter International Inc.,

Mr. Robert L. Parkinson, Jr.

Mr. and Mrs. Philip J. BazelidesMr. Howard BernickCarol Lavin Bernick Family FoundationMr. and Mrs. Daniel S. BernsteinMs. Alecia Blake andMr. Curtis RudbartMr. and Mrs. Robert S. BlankBulley & Andrews, LLCMr. Louis C. CamilleriMr. and Mrs. Arthur CarterMr. and Mrs. Marvin H. DavidsonMr. David DeckelbaumMr. and Mrs. Charles M. DikerElan Pharmaceuticals, Inc.Emory UniversityMs. Mary C. FarrellFrontenac Company, LLCMr. Richard GersonMr. and Mrs. Henry GoldbergMr. and Mrs. King W. HarrisMs. Marlene Hess and Mr. James D. ZirinMr. Gregory JonesThe Kaneff FoundationMr. and Mrs. Michael KatzkeMr. and Mrs. Howard KesslerMr. and Mrs. Lester KnightMr. Dan Lufkin, The Peter Jay Sharp

FoundationMs. Michelle MacDonaldMr. William E. MayerMr. Samuel M. MencoffMr. and Mrs. WilliamMillerMr. and Mrs. Marc S. MollerMotorola Solutions, Inc.Pfizer Inc.Mr. Thomas PheasantMr. and Mrs. Michael PiercePLVTZ GUC Trust, Mr. Jeffrey CohenMr. and Mrs. Robert PrinceMs. Lita RosenbergMr. and Mrs. Mortimer SacklerMs. Sharon T. Sager and Mr. Loring Swasey,

UBS Private WealthSaks Fifth AvenueMr. and Mrs. Nathan SandlerMr. and Mrs. Paul C. Schorr IIIAnna and John J. Sie FoundationThe Sun-Times FoundationMs. Sally Susman, Pfizer Inc.Ms. Mary Rose TaylorMr. and Mrs. Andrew Tisch

2012 Donors


Mr. and Mrs. John L. VogelsteinMs. Giselle F. Wagner and

Mr. Paul A. MyersonNina W. Werblow Charitable TrustMr. and Mrs. Robert B. Zink

$5,000 to $9,999Mr. and Mrs. James D. AbramsThe Anne and Ronald Abramson

Family FoundationMs. Deidre AdkinsAon FoundationMr. and Mrs. Robert BanksMr. and Mrs. Ron Baron, Baron Capital

FoundationMr. and Mrs. Gustavo A. CisnerosMr. Michael T. CohenMr. Robert O. DelaneyMr. and Mrs. Warren DiamondMr. and Mrs. Craig DuchossoisMr. and Mrs. Paul EdgerleyMr. and Mrs. Joel S. EhrenkranzFather's Day/Mother's Day Council, Inc.Mr. and Mrs. George FerrisMr. and Ms. Dennis FitzSimonsForest Laboratories, Inc.Mr. and Mrs. Thomas FriedmanMr. and Mrs. Richard I. FurmanThe Gabelli FundsThe Giants Foundation, Inc.GlaxoSmithKlineMr. and Mrs. Roger HertogJanssen Research & Development-

Johnson & JohnsonMr. and Mrs. Harry P. KamenKekst and Company IncorporatedLazo FoundationMr. and Mrs. Daniel S. LoebMrs. Holly MadiganMs. Barbara ManilowThe Marc Haas Foundation,

Mr. and Mrs. Stanley ShumanMr. and Mrs. Kelly MartinMs. Carlyn McCaffreyMr. and Mrs. John McCambridgeMr. and Mrs. AndrewMcKennaMichael J. Fox Foundation for

Parkinson's ResearchMs. Jennifer Miller and Mr. Mark EhretMr. Ira MillsteinMr. Charles MoffettMr. and Mrs. Andy MollerNational Multiple Sclerosis SocietyMr. Michael O'HalleranMr. and Ms. William OsbornMrs. Janet Kelly Phillips

Margot and Thomas PritzkerFamily Foundation

Ms. Patricia QuickMs. Margaret RiceMs. Liz Robbins and Mr. Doug JohnsonMs. Pilar Crespi Robert and Mr. Stephen

RobertMr. and Mrs. Thomas RobertsMr. and Mrs. Elihu RoseMs. Emily RoseMr. and Mrs. Jack RudinPatrick G. and Shirley W. Ryan FoundationMs. Patricia Bennett SagonMr. and Mrs. Richard E. SalomonMr. and Mrs. Gerald SchaefferMr. and Mrs. George W. SchieleThe Sheldon H. Solow FoundationSouth Coast Capital Corporation,

Mr. Philip LovettMrs. Edward D. StoneMr. and Mrs. Donald ToberMrs. Elizabeth van MerkensteijnTrish and George Vradenburg,

USAgainstAlzheimer’sMrs. Jeanette Sarkisian Wagner and

Dr. Paul A. WagnerMr. and Mrs. John F. WalshWeil, Gotshal & Manges Foundation Inc.Wheels, Inc.Mrs. Malcolm Hewitt WienerThe Honorable Corinne Wood and

Mr. Paul WoodMs. Linda ZambelliMr. and Mrs. Carl ZelinskyMr. Mortimer B. Zuckerman

$1,000 to $4,999Anonymous (3)Mr. and Mrs. Frederick R. AdlerMs. Susan AggerMs. Tina AlsterMr. Ronald A. AltmanMr. and Mrs. John AmboianMr. and Mrs. Steven AmesMr. Roger AndersonMs. Gloria AndersonMr. Richard AneserMr. and Mrs. John AngeloMr. Artemis AnninosMr. Edgar BachrachThe David and Barbara Baldwin

FoundationMs. Mercedes T. BassMr. Dennis Basso and

Mr. Michael CominottoBaxter Healthcare CorporationMr. Leonard J. Bencivenga

Dorothy G. Bender FoundationMr. and Mrs. Bruce BergerDr. Arnold BermanThe Honorable and Mrs. Stuart BernsteinBernstein Family FoundationBioFocusMr. Steve BlacherMr. and Mrs. Wolf BlitzerMr. and Mrs. Bernard BloomMr. and Mrs. Roy BostockDr. and Mrs. Mark K. BowenMrs. Susan BraddockMr. and Mrs. Lawrence BrandtDr. Eric BravermanMr. Daniel J. BrigatiMr. and Mrs. Alan BubesMrs. Melva Bucksbaum and

Mr. Raymond LearsyMr. and Mrs. Leonard BurkaMs. Sharon BurkaMs. Bari BurmanMs. Mary K. BushMr. and Mrs. Louis CaceresMr. and Mrs. William CafritzMs. Caitrine CallisonMr. and Mrs. Charles CangroMs. Giosetta CapriatiMr. John K. CastleMr. and Mrs. Wright CaughmanMs. Lois Chiles and Mr. Richard GilderMs. Jeanne ColemanMr. and Mrs. Charles Collat, Sr.Mr. and Mrs. Mark ColmanMr. Owen CondonMr. and Mrs. Bob CooneyMr. and Mrs. John D. CooneyMr. and Ms. Peter H. CoorsMrs. Joyce CowinMs. Brittain B. CudlipMr. and Mrs. Arnaud de BorchgraveMr. John D. DemseyMr. Paul DeslongchampsMr. Lawrence DoyleDr. and Mrs. Ronald DozoretzMr. and Mrs. Rodman DrakeMr. and Mrs. Kenneth DubersteinMr. and Mrs. Todd EagleMr. and Mrs. John EastmanEckert Seamans Cherin &Mellott, LLCMr. and Mrs. Lewis M. EisenbergMr. and Mrs. Richard EldenAmbassador and Mrs. Edward E. ElsonMrs. Sondra Berman Epstein and

Mr. Sidney EpsteinMr. and Mrs. Melvyn J. EstrinMr. Stuart M. Fain

16

Mr. and Mrs. William FarleyMs. Samia FaroukiMr. and Mrs. David C. FarrellMr. and Ms. W. J. FarrellMr. and Mrs. Kenneth FeldMr. and Mrs. Marshall FieldMr. and Mrs. Harry FieldsDr. Howard FillitMs. Marcia FrenchMrs. Emily T. FrickMs. Charlotte Moss and

Mr. Barry FriedbergFross Zelnick Lehrman & Zissu P.C.Ms. Mary GalvinGantz Family FoundationMs. Brooke Garber and

Mr. Daniel M. NeidichMr. and Ms. Robert P. GarrettMr. Bruce GelbGenentech USAMr. David GersonMr. Andrew D. GilbertAmbassador and Mrs. Joseph B. GildenhornMr. and Mrs. Jim GlassmanMr. Joseph B. GlossbergMr. David GoodesMr. Sheldon GordonMr. and Mrs. Ian GrahamMrs. and Mrs. Richard GrayMr. Peter GreenMs. Sylvia GreenbergMr. Alexis GregoryMr. and Mrs. Philip M. GrossMr. and Mrs. Martin GrussMs. Agnes GundThe Geoffrey Gund FoundationHagin Capital LLCMs. Judy Jackson andMr. Bruce HaimsMr. and Mrs. William H. Hamm IIIMs. Jane HarmanMr. Chris HarrisMs. Ellen R. HarrisMr. Kenneth H. HeitnerMr. and Mrs. John HellerMr. and Mrs. David HellerMr. and Mrs. Barnett Helzberg, Jr.Mr. Terrence HendricksMr. and Mrs. Lawrence HerbertMrs. Ronnie F. HeymanMr. and Mrs. John Hickey, Jr.Mr. John HigginsMs. Catherine HirschMs. Mellody L. HobsonMs. AnnMarie Huebner and

Mr. Ross P. WallerMs. Berna Huebner

Mr. and Mrs. Kit IllickMs. Deborah ImperatoreMr. and Mrs. Verne G. IstockThe Melvin and Rosalind Jacobs

Family FoundationMr. and Mrs. Richard JaffeMs. Nada JainMr. David JarvisMr. and Mrs. Maurice JenningsMr. Christopher JohnsonJordan Industries International LLCJSW Lifesciences GmbHLady Barbara Thomas JudgeRita J. and Stanley H. Kaplan Family

Foundation, Inc.KasperMr. and Mrs. John KelseyMr. and Mrs. James C. KennedyMr. and Mrs. Shaker KhayattDr. and Mrs. Israel KoganMr. Paul KonstantMr. and Mrs. Frederick A. KrehbielMr. and Mrs. H. Fred Krimendahl IIMr. and Mrs. Peter KrulewitchMs. Joan Krupskas and Mr. Ted BarbourMs. Elizabeth Szancer Kujawski and

Mr. Tom ZoufalyMr. Jeff KurtzMr. and Mrs. Richard LandauMs. Marilyn Brody LaneMs. Claudine LarocqueThe Honorable and Mrs. Ronald S. LauderMr. William P. LauderMr. and Mrs. Brian LawlorMs. Ginger LaythamLazard Freres & Co. LLCMs. Alexandra Lebenthal and

Mr. Jeremy DiamondMr. and Mrs. Melvin LenkinMs. Marcia Levine and Mr. Pierre LevaiMr. and Mrs. Noel LevineMr. and Mrs. Steven LevyMr. and Mrs. Samuel H. LindenbaumMrs. Anne H. LindgrenThe Meno Lissauer Foundation Inc.,

Ms. Alison McCall and Mr. Peter EleilMr. Leonard D. LitwinMr. and Mrs. Carl LobellElizabeth and Jeff Louis FoundationMrs. Nancy LynnMr. and Mrs. Harry MackloweMr. and Mrs. Vincent A. MaiThe Honorable and Mrs. Frederic V. MalekMr. Mark MaltzmanMr. and Mrs. James C. MarlasMr. and Mrs. Bennett MarshallJack C. Massey Foundation

Mr. and Mrs. Jonathan P. MayMs. Katherine MayerMrs. Shirley Maytag-KingMs. Alison McCall and Mr. Peter ElielMs. Anya McComseyMs. Judy McLarenMs. Robin MeltzerMr. Gilles MendelMr. and Mrs. SamMichaelsMs. Sandra Miele, The Hampshire

CompaniesMr. and Mrs. Donald K. MillerMr. and Mrs. James N. MillsMr. and Mrs. AndrewMillsMs. Karen MoranMr. Patrick R. MorrisMr. and Mrs. Lucian Morrison IIIMorgan StanleyMr. and Mrs. Allan MuchinMulé Family FoundationMr. and Mrs. Mark R. NeamanMs. Judith E. NeisserNeuroDetective International Inc.Neurophage Pharmaceuticals, Inc.Mr. and Mrs. Howard NewmanMr. and Mrs. William A. NitzeMs. Virginia NortonMr. and Mrs. Larry NussdorfMr. Jon OldMs. Hannah PakulaPatheonMs. Darlene Pasquill and Mr. Mike HillerDr. Steven PaulMr. and Mrs. Richard S. PearmanMs. Erica PeitlerMr. and Mrs. John PomerantzMs. Phebe Farrow PortPsychoGenics, Inc.Ms. Deirdre QuinnreMYNDMr. Clayton ReynoldsMr. and Mrs. Lewis RiceMs. Denise RichRichard Gray Gallery L.P.Judith RipkaMrs. Sheila Johnson RobbinsMrs. Anita RoselleMr. Joseph RosenblattMs. Nina RosenwaldMr. Ronald RosnerMr. and Mrs. Laurence RosoffMrs. Janet C. RossMr. and Mrs. Wilbur L. Ross, Jr.Dr. and Mrs. Ronald M. RothMr. and Mrs. Howard J. RubensteinThe Shelley & Donald Rubin Foundation


Mrs. Genevieve McSweeney RyanMr. Kevin M. RyanMr. and Mrs. David SableMr. and Mrs. Sal SalibelloSatori Pharmaceuticals Inc.Mr. and Mrs. George Saunders, Jr.Mr. Peter M. ScheerMr. and Mrs. Lloyd SchermerMr. David T. SchiffMr. and Mrs. Mitchell SchrageMrs. Barbara SchwartzMr. Edmondo SchwartzMr. and Mrs. Chris SegalMs. Pamela Seymon and

Mr. Robert SchumerThe Susan Stein Shiva FoundationThe Carlynn and Lawrence Silverman

Family Foundation Inc.Mr. Thomas SlaterMr. and Mrs. Joshua SlocumMr. and Mrs. Albert H. SmallMr. and Mrs. Albert Small, Jr.Mr. and Mrs. Joseph E. SmithMs. Angela Smith DomzalMr. and Mrs. Richard SolomonPeter J. Solomon Company, LPMr. Maurice SonnenbergMs. Lisa B. SpikellMs. Emily SpitzerMr. and Ms. Jeffrey SteinbergDr. Philip StiegMr. and Mrs. David A. StockmanMs. Eleanor SullivanT. Rowe Price Foundation, Inc.Ms. Andrea TaetleMr. and Mrs. A. Alfred TaubmanMs. Laurie M. TischMs. Jamie TischMs. Lee TraubMs. Alexandra Trower and

Mr. Jon LindseyMs. Eunice C. ValdiviaMs. Sahba Vaziri and Mr. Ali RezaViking Global Investors LPMr. and Mrs. Curt von BoetticherMr. and Mrs. Michael VoslowMs. Gretchen A. WayneMs. Jane Greenwald and

Mr. Lawrence A. WeinThe John L. & Sue AnnWeinberg

FoundationMr. and Mrs. Walter WeinerMs. Linda WeinsteinMr. and Mrs. Ronald WeintraubDr. Arthur C. WeisenseelMr. MasonWeiszDr. Tina West

The Honorable and Dr. Marcus WilliamsMs. Jan WillingerMr. and Mrs. Robert ZarneginMr. and Mrs. Shelton Zuckerman

2012 In-Kind DonorsAbrielle Fine Linens & LingerieAmaryllis FlowersArt of GivingBedford Post InnBLT SteakBobbi BrownBottega VenetaBumble & bumble.Café MilanoCarolina HerreraClay & Co.Colicchio & SonsColliers International NY LLCCreative Parties, Ltd.David BurkeJay and Cindy DeFrancescoDelta AirlinesDenihan Hospitality GroupDesign CuisineDiener Jewelers – Allison Diener

PerlmutterDKNYDouglas HannantSilvia and Peter DreyfussEckert Seamans Cherin & Mellott, LLCThe Estée Lauder Companies Inc.Fairmont Hotels & ResortsFiola RestaurantThe Four Seasons RestaurantFour Seasons Hotel, Washington, DCLenny GordonGotham Dream CarsHealthyChocolate NYHickey FreemanHu’s Shoes + Hu’s WearJennifer Miller JewelryJenny Ng DesignsJetBlue AirwaysJohnny Brookheart JewelersJudith LieberJudith RipkaJust CakesKimpton Hotels & RestaurantsKnightsbridge Management CorporationElise and Marc LefkowitzLe Relais de Venise L’EntrecôteLincoln Financial GroupMarchesaMartek Corporation

In 2012, gifts were

made to the ADDF

in honor of the

following individuals:

Milton Lewin and Milian BeckerKaren Weise and Noah BuhayarAmy DiGesoEmory University ADRCAgnes FarrellHoward FillitIngrid FloresNancy FoxmanRosemary FurmanFrances R. GewirzMelvin R. GoodesMary Alice GriffinRon JohnsonLeonard A. LauderAngeline LewisThelma "Bunny" LlyodRita LulloNancy LynnMarilu MarshallLee MotlerFred MyersMalene Moore NadeauDolly ReedPhoebe RiceTom and Cece RickettsPessie Sue Weir andMargaret Roberson

Rose SantoroMary Ellen SchaeferPeter J. SolomonB.G. StarnesDorothy SteinJoan Sutton StrausMary Rose TaylorElsie WilliamsBarbara Wolfson

18

We are grateful to all who contributed to the ADDF in 2012.For a complete list of donors, please visit www.AlzDiscovery.org

Susan and Emilio MattMetrokaneMolyvos Restaurant and the

Livanos FamilyMontblancNancy CorzineNew York JetsOheka CastleOrganic AvenuePassion Food HospitalityPCH FilmsPirelli Tire North AmericaPrestige Beverage GroupThe Ritz-Carlton Destination ClubThe Ritz-Carlton, Washington, DCRoyal International Travel Services, Inc.Saks Fifth AvenueScalamandréJanet Sussman and Michele WeinsteinSharon T. SagerTeuscher Chocolates of SwitzerlandFabio and Maria TrabocchiThe West Institute for Skin, Laser and

Body ContouringW South Beach Hotel and ResidencesZagat

Legacy Giving

Charitable bequests to the ADDF help us to fulfill our mission toaccelerate the discovery of drugs to prevent, treat and cure Alzheimer’sdisease, related dementias and cognitive aging.

Simply use this suggested language in your will or living trust:“I bequeath [dollar amount/percentage] to the Alzheimer’s DrugDiscovery Foundation, a New York State not-for-profit organization.”

If you already have a will or living trust, you may add the ADDF as abeneficiary through a codicil or trust amendment. Bequests to theADDF are not subject to estate tax. Consult with your attorney or otheradvisors to make sure that your bequest makes sense as part of youroverall estate plan. For more information about ways to give, pleasecall 212-901-8000.

The ADDF remembers

and honors those taken

by Alzheimer’s in 2012

by continuing to fight

for a cure.

Melba BickhamJean T. BrigatiPaul ConnollyMary Louise DealEdwin EverittBeverly HarrisIrwin “Win” HechtThomas HendricksGloria HirtzShirley LichawRonald LoebLydia MelendezJoan MorseBill OpelkaConnie RicePhyllis RosenthalWarren E. Siegmond

“The lifegiven us bynature isshort, butthememoryof a life wellspent iseternal.”

—Cicero


Corporate and FoundationMembership CircleAlzheimer’s Foundation of AmericaThe Association for

Frontotemporal DegenerationBrightFocus FoundationCharles River LaboratoriesErnst & Young, LLPThe Estée Lauder Companies Inc.First Republic BankFlexjetGraff DiamondsLe Papillon Ltd.Lewy Body Dementia AssociationMerck Research LaboratoriesThe Neiman Marcus GroupNorthern TrustPfizerSaks Fifth AvenueSotheby’sStaplesTommy Hilfiger Corporate

FoundationUBS

Preclinical Drug Discovery Program —Academic

Carmela R. Abraham, PhDBoston University School of Medicine,Boston, Massachusetts

Development of Klotho Enhancers asNovel Therapeutics for ADAWARD: $196,421

Antonino Cattaneo, PhDScuola Normale Superiore, Pisa, Italy

Preclinical development of "painless" humanNerve Growth FactorAWARD: $175,000

Marcie Glicksman, PhDHarvard Neurodiscovery Center, Cambridge,MassachusettsCollaborative CNS Screening InitiativeAWARD: $123,433*Beyond Batten Disease Foundation/MultipleSclerosis Society

Anil Gulati, MD, PhDMidwestern University, Downers Grove, Illinois

Nanocarrier formulation of ETB receptor agonist,IRL-1620, for the treatment of Alzheimer's diseaseAWARD: $96,694

Andrew Horti, PhDJohns Hopkins University, School of Medicine,Baltimore, Maryland

Cannabinoid CB2 radioligands for PET imagingof neuroinflammation in Alzheimer's diseaseAWARD: $149,970

Li Huang, PhDDuke University, Durham, North Carolina

Proteasome activator as drug candidates inAlzheimer's diseaseAWARD: $100,000*Alzheimer’s Drug Discovery/Alzheimer’s Foundationof America Award to Accelerate Drug Discovery

Jeff Kuret, PhDOhio State University, Columbus, Ohio

Imaging agents for diagnosis of tauopathicneurodegenerative diseasesAWARD: $150,000*Alzheimer’s Drug Discovery Foundation/Alzheimer’s Foundationof America Award to Accelerate Drug Discovery

Ana Martinez, PhDMedicinal Chemistry Institute-CSIC, Madrid, Spain

Evaluation of cognition and hippocampal neurogenesisafter oral administration of a phosphodiesterase 7 inhibitorin an Alzheimer's disease mice modelAWARD: $120,000

Alzheimer’s Drug Discovery Foundation of Canada Program14%

ADDF-New York Academy of Sciences Partnership Program2%

ADDF-Lewy Body Dementia Association Partnership Program3%

ADDF-Association for Frontotemporal DegenerationPartnership Program 6%

ADDF-Charles River Aging Partnership Program3%

ADDF-Belfer ApoE Therapeutics Innovation Program7%

Program to Accelerate Clinical Trials (PACT)27%

Preclinical Program38%

ADDF 2012 Grants

20

Elliot Mufson, PhDRush University Medical Center, Chicago, IllinoisCSF proNGF: a putative biomarker for Alzheimer's diseaseAWARD: $130,734

John Schetz, PhDUniversity of North Texas Health Science Center,Fort Worth, Texas

Target-based discovery of druggable regulators ofperoxynitrite-induced nitration as a novel treatmentstrategy for Alzheimer's diseaseAWARD: $199,803

Eugenia Trushina, PhDMayo Clinic Rochester, Rochester, Minnesota

Mechanism of restoration of mitochondrial functionby tricyclic pyrone compoundsAWARD: $181,757

Neil Vasdev, PhDMassachusetts General Hospital/Harvard Medical School,Charlestown, Massachusetts

Radiopharmaceutical Development for ImagingMetabotropic Glutamate Subtype 5 Receptors (mGluR5)in AD patients with PETAWARD: $175,000

Yan Zhang, PhDThe University of Texas at Austin, Austin, Texas

Selective Inactivation of Human Phosphatases forNeuronal RegenerationAWARD: $132,960

Biotechnology Program — Preclinical

Joseph Harding, PhDM3 Biotechnology, Inc., Pullman, Washington

Development of small molecule hepatoctye growthfactor mimetic for the treatment of dementiaAWARD: $174,993

Mark Rampy, PhDCohBar, Inc., Pacific Palisades, CaliforniaOptimization and Preclinical Development of a NovelTherapeutic Peptide For Alzheimer's DiseaseAWARD: $205,260

Thadd Reeder, PhDGlialogix, Inc., San Francisco, CaliforniaTesting of GLX1112 in an Alzheimer's mouse modelAWARD: $207,000

Lawrence Wennogle, PhDIntra-Cellular Therapies, Inc., New York, New York

Validation of a Novel Target Mechanism to CounterProgression of Alzheimer's DiseaseAWARD: $219,667

Program to Accelerate Clinical Trials (PACT)

Sandra Black, MD, FRCP(C)^Sunnybrook Research Institute, University of Toronto,Toronto, Canada

Sartans to Slow Alzheimer's Disease: A Randomized,Open-Label, Head-to-Head, Proof-of-Concept Study ofAngiotensin Receptor Blockers Versus ACE Inhibitorsin Hypertensive Mild-Moderate AD Patients usingVentricular Enlargement as Primary OutcomeAWARD: $992,388*The W. Garfield Weston Foundation/Alzheimer’s Drug DiscoveryFoundation of Canada Award

Steven Estus, PhDUniversity of Kentucky Research Foundation,Lexington, Kentucky

Translating genetics into biomarkers and therapies:apoE/Ab and apoJ/Ab complex levels and lipidationstate as AD biomarkers modulated by VPAAWARD: $117,000

Allan Levey, MD, PhDEmory University School of Medicine,Atlanta, GeorgiaA phase IIa, double-blind, placebo-controlled,biomarker study of atomoxetine in subjects withmild cognitive impairmentAWARD: $447,900*2012 Fund a Scientist Auction Award

Olga Meulenbroek, PhDRadboud University Medical Centre,Nijmegen, The Netherlands

Nilvad add-on study: The effects of nilvadipine on bloodpressure, cerebral autoregulation, -blood flow and -damagein Alzheimer's diseaseAWARD: $380,224

Ana Pereira, MDThe Rockefeller University, New York, New York

Glutamatergic Dysfunction in Cognitive Aging:Riluzole in Mild Cognitive ImpairmentAWARD: $250,000

BiotechnologyGary Landreth, PhDReXceptor Therapeutics, Cleveland, Ohio

A Randomized Controlled Study to Evaluate the Effect ofBexarotene, an RXR Agonist, on beta-Amyloid andApolipoprotein E Metabolism in Healthy SubjectsAWARD: $750,000*The Charles Evans Foundation/Alzheimer’s Drug Discovery Award;BrightFocus Foundation


ADDF-Belfer ApoE TherapeuticsInnovation Program

Mary Jo LaDu, PhDUniversity of Illinois at Chicago, Chicago, Illinois

Modulation of human apoE isoform levels as atherapeutic target using a new Alzheimer's diseasetransgenic mouse modelAWARD: $91,000*Alzheimer’s Drug Discovery Foundation/The Samuel FreemanCharitable Trust Award to Accelerate Drug Discovery

Cheryl Wellington, PhDUniversity of British Columbia Hospital,Vancouver, CanadaNovel modulators of apoE functionAward: $148,000

BiotechnologyRick Jack, PhDMadera Biosciences, Inc., San Diego, California

In vitro and in vivo optimization of ApoEmodulators for Alzheimer's diseaseAWARD: $298,500

ADDF-Charles River Aging Partnership Program

Khalid Iqbal, PhDNew York State Institute for Basic Research inDevelopmental Disabilities, New York, New York

Rescue of Neuronal Plasticity and CognitiveImpairments in Aged RatsAWARD: $254,450

ADDF-Association for FrontotemporalDegeneration Partnership Program

Nigel Cairns, PhDWashington University, St. Louis, MissouriRestoring progranulin in frontotemporal diseaseAWARD: $156,990

Jeffrey Rothstein, MD, PhDJohns Hopkins University, School of Medicine,Baltimore, Maryland

Development of Antisense therapy and Therapeuticbiomarker for C9orf72 FTD/ALS mutation patientsAWARD: $125,856

W. Haung Yu, PhDColumbia University Medical Center,New York, New York

Development of small molecule enhancers ofautophagy for the clearance of protein aggregatesand treatment of FTDAWARD: $149,642

ADDF-Lewy Body Dementia AssociationPartnership Program

Omar El-Agnaf, PhDUnited Arab Emirates University, Al-Ain,United Arab Emirates

Testing a combination of CSF biomarkers fordiscriminating dementia with Lewy bodies fromother neurodegenerative disorders and controlsAWARD: $100,000

Michelle Mielke, PhDMayo Clinic Rochester, Rochester, Minnesota

Plasma lipidomic and alpha-synuclein comparisonof individuals with alpha-synuclein, amyloid, ornormal pathologyAWARD: $100,000

ADDF-New York Academy of SciencesPartnership Program

Douglas Galasko, MDUniversity of California, San Diego, La Jolla, California

Development of synaptic biomarkers related toAMPA-receptor trafficking in Alzheimer's DiseaseAWARD: $140,000

Conference Grants

Jennifer Henry, PhDNew York Academy of Sciences, New York, New York

Targeting the Vasculature in Alzheimer's Disease andVascular Cognitive ImpairmentAWARD: $16,719

Sharon Hesterlee, PhDAssociation for Frontotemporal Degeneration,Philadelphia, PennsylvaniaClinical Development in Frontotemporal DegenerationAWARD: $5,000

George VradenburgUSAgainstAlzheimer's Network, Washington, DC

Alzheimer's Talks: "What's in the new National Alzheimer'sPlan to stop Alzheimer's by 2025?"AWARD: $10,000

David Woodland, PhDKeystone Symposia on Molecular and Cellular Biology,Silverthorne, ColoradoNew Frontiers in Neurodegenerative Disease ResearchAWARD: $2,500

22

Statements of Financial PositionUnaudited

Assets 12/31/12Cash and cash equivalentsOperating $ 2,556,159Restricted 182,896

Total cash and cash equivalents 2,739,055

Investment, at fair value 8,115,777

Contributions receivable 2,742,129

Other assets 16,224

Total assets $ 13,613,185

Liabilities and Net AssetsLiabilitiesAccounts payable and accrued liabilities $ 62,806Grants payable 7,485,431Deferred revenue 132,049Due to the Institute for the Study of Aging, Inc. 9,763

Total liabilities 7,690,049

Net assetsUnrestricted 4,920,240Temporarily restricted 1,002,896

Total net assets 5,923,136

Total liabilities and net assets $ 13,613,185

Statement of ActivitiesUnaudited

Change In Net Assets 12/31/12

Support and RevenuesSupportContributions and grants $ 5,930,926In-kind contributions from the Institute for the

Study of Aging, Inc. 2,753,087Proceeds from special events, net of direct expenses 3,349,090

RevenuesGrant Returns 133,860Conference registration fees and other income 220,582Interest income 6,352

Total support and revenues 12,393,897

ExpensesProgram services 8,004,920Fund raising 1,051,466Management and general 532,910

Total expenses 9,589,296

Change In net assets 2,804,601

Net assets, beginning of year 3,118,535

Net assets, end of period $ 5,923,136

Audited financials available upon request


Alzheimer’s DrugDiscovery Foundation

ADDF 2012 Board

2012 Board of Governors

Honorary Chairman

Sandra Day O'Connor

Co-Chairmen

Leonard A. Lauder

Ronald S. Lauder

President

Nancy Corzine

Robert A. Belfer

Bonnie Pfeifer Evans

Lady Lynn Forester de Rothschild

Melvin R. Goodes

Nancy Goodes

Randal Sandler

Alice Shure

Peter J. Solomon

Sally Susman

Paula Zahn

Ex Officio

Howard Fillit, MD

Nancy Lynn

Officers

Lisa Somar

Joan Krupskas

2012 Board of Overseers

Co-Chairmen

Susan Roth Katzke

Sharon T. Sager, CIMA

Randal Sandler

Carol Seabrook Boulanger

Charles Cangro

Faith Perlmutter Diamond

Julie Eskay-Eagle

Allan Green, MD, PhD, JD

Christopher Johnson

Alexandra Lebenthal

Elise Gelman Lefkowitz

Philip Lovett

Emilio Matt

Phebe Farrow Port

Joan Sutton Straus

Mary Rose Taylor

Alison Zaino

Linda S. Zambelli

Joint Annual Board Meetingof the Board of Governorsand the Board of Overseers.December 12, 2012

As of December 31, 2012

For more information about the ADDF, please visitwww.AlzDiscovery.org24

ADDF 2012 Staff

As of December 31, 2012

Howard Fillit, MDExecutive Director and Chief Science Officer

Science

Diana Shineman, PhDDirector, Scientific Affairs

Rachel Lane, PhDAssistant Director, Scientific Affairs

Penny Dacks, PhDAssistant Director, Aging and Alzheimer’sDisease Prevention

Filomena MachlederAssistant Director, Institutional Partnerships

Niyati ThakkerGrants Manager

Sara ClassenCoordinator, Conferences and Meetings

Natalie RomatzCoordinator, Conferences and Meetings

Administration

Aspasia MoundrosExecutive Assistant

Nancy LynnExecutive Director and Chief Operating Officer

Development

Vina OrdenDirector, Major Gifts

Jayme RubrightDirector, Corporate and Strategic Relations

Kate PolidoriAssistant Director, Special Events

Allison SawczynAssistant Director, Development

Carrie TracyAssistant Director, Special Events

Dina MillerDevelopment Associate

Elizabeth FeskoeCoordinator, Database and Development

Mollie WeinSpecial Events Coordinator

Finance

Ethan HutchinsonDirector, Finance and Administration

Diane DuongFinance Manager

57 West 57th Street, Suite 904New York, NY 10019Phone: 212 901-8000Email: [email protected]

www.AlzDiscovery.org

TheADDFhasgrantednearly $60million tofundover400programsin 18countries.

Conquering Alzheimer’s Through Drug Discovery

2012 Annual Report

Documents

Transcript of 2012 Annual Report